Chronic Kidney Disease (CKD) Clinical Trial and Study
Patients with Chronic Kidney Disease Stage 4
Who Can Participate in the Chronic Kidney Disease Trial (Clinical Study)?
You are eligible to participate if the following conditions are met:
You will not be eligible if the following conditions apply
What is this Chronic Kidney (Renal) Disease trial about?
The purpose of this clinical study is to evaluate the safety and efficacy of an investigational medication in individuals with chronic kidney (renal) disease stage 4. This purpose of this FDA-approved Investigational drug is to determine safety and its ability to reduce or slow progression of patients who have been diagnosed with Chronic Kidney Disease (CKD) stage 4 and how it impacts on their quality of life.
About CKD stage 4 Clinical trial
The objective of this clinical study is to evaluate the safety and efficacy of an investigational medication in patients with chronic kidney disease stage 4. CKD is a condition characterized by gradual loss of kidney function over time. Chronic kidney disease is classified based on kidney function measured with glomerular filtration rate (GFR) into several stages of 1, II, III, IV, and V. The CKD stage V is advanced stage of kidney disease where the kidneys have lost nearly all ability to function effectively and ultimately dialysis or kidney transplant is needed to live. Treatment may slow the decline in kidney function and failure.
Study Drug and Purpose: US-APR2020 is a probiotic formulation intended to restore the gut bacteria balance to improve the removal of uremic toxins in the bowel in CKD patients. This Phase 2b study is to evaluate the safety and efficacy of the probiotics in the management of patients with CKD Stage IV.
Study Regimen: You'll be given either study drug or placebo, oral, twice a day for 6 months.
Study Visit: One screening visit and 6 follow-up office visits (Day 1, 8, 30, 60, 90. And 180) that include physical exams and blood tests. Study Cost: All study drugs and tests are provided by the sponsor.
IRB Approved As
Modified at the
Sep 12, 2021